CJC-1295 (without DAC) (Modified GRF 1-29)

Short-Acting Growth Hormone Releasing Hormone Analog

Weight: 3,367.97 Da
Half-life: 30 minutes - 2 hours
Chain: 30 amino acids
5 studies
2009 latest
1 recent
Well Studied
Dose 100-300mcg per injection
Frequency 2-3 times daily (morning, post-workout optional, bedtime)
Cycle 12-16 weeks
Storage Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days
Accumulation Plotter

Community Research

Join others researching CJC-1295 (without DAC) — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 with DAC, this version preserves natural GH pulsatility without continuous elevation.

Mechanism of Action

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH

Molecular Data

Molecular Weight
3,367.97 Da
Chain Length
30 amino acids
Type
GHRH analog
Amino Acid Sequence
One-letter: YADAIFTNSYRKVLAQLSARKLLQDILSRK
H₂N
Y 1
O ‖ C
N
A 2
O ‖ C
N
D 3
O ‖ C
N
A 4
O ‖ C
N
I 5
O ‖ C
N
F 6
O ‖ C
N
T 7
O ‖ C
N
N 8
O ‖ C
N
S 9
O ‖ C
N
Y 10
O ‖ C
N
R 11
O ‖ C
N
K 12
O ‖ C
N
V 13
O ‖ C
N
L 14
O ‖ C
N
A 15
O ‖ C
N
Q 16
O ‖ C
N
L 17
O ‖ C
N
S 18
O ‖ C
N
A 19
O ‖ C
N
R 20
O ‖ C
N
K 21
O ‖ C
N
L 22
O ‖ C
N
L 23
O ‖ C
N
Q 24
O ‖ C
N
D 25
O ‖ C
N
I 26
O ‖ C
N
L 27
O ‖ C
N
S 28
O ‖ C
N
R 29
O ‖ C
N
K 30
COOH
Tyr
1

Tyrosine

Position 1

Ala
2

Alanine

Position 2

Asp
3

Aspartic Acid

Position 3

Ala
4

Alanine

Position 4

Ile
5

Isoleucine

Position 5

Phe
6

Phenylalanine

Position 6

Thr
7

Threonine

Position 7

Asn
8

Asparagine

Position 8

Ser
9

Serine

Position 9

Tyr
10

Tyrosine

Position 10

Arg
11

Arginine

Position 11

Lys
12

Lysine

Position 12

Val
13

Valine

Position 13

Leu
14

Leucine

Position 14

Ala
15

Alanine

Position 15

Gln
16

Glutamine

Position 16

Leu
17

Leucine

Position 17

Ser
18

Serine

Position 18

Ala
19

Alanine

Position 19

Arg
20

Arginine

Position 20

Lys
21

Lysine

Position 21

Leu
22

Leucine

Position 22

Leu
23

Leucine

Position 23

Gln
24

Glutamine

Position 24

Asp
25

Aspartic Acid

Position 25

Ile
26

Isoleucine

Position 26

Leu
27

Leucine

Position 27

Ser
28

Serine

Position 28

Arg
29

Arginine

Position 29

Lys
30

Lysine

Position 30

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Growth Hormone
Natural GH Pulse Restoration most effective

Restores natural GH pulsatility patterns in aging individuals.

IGF-1 Enhancement effective

Elevates IGF-1 through enhanced GH secretion.

Pituitary Support effective

Supports pituitary axis without suppression of natural function.

Anti-Aging
Muscle Mass Preservation effective

Supports maintenance of lean muscle mass through GH elevation.

Bone Density Maintenance effective

Supports bone health through GH-mediated pathways.

Skin Elasticity moderate

Improvements in skin quality through collagen synthesis.

Recovery
Exercise Recovery moderate

Enhanced recovery from training through GH elevation.

Sleep Quality moderate

Improved sleep architecture with bedtime dosing.

Dosing Protocols

Subcutaneous injection is the only effective route. Best administered on empty stomach, 30+ minutes away from food.

GoalDoseFrequencyRoute
Anti-Aging/Wellness100mcg2x daily (morning and bedtime)SubQ
Body Composition100-150mcg3x daily (morning, post-workout, bedtime)SubQ
Maximum GH Release200mcg2-3x daily with GHRPSubQ
Sleep Enhancement100-200mcgOnce at bedtimeSubQ

Reconstitution Instructions

Materials Needed:
  • Bacteriostatic water
  • Insulin syringes (29-31 gauge)
  • Alcohol swabs
  • Sterile work surface
  1. 1 Clean vial tops with alcohol pad and allow to dry
  2. 2 Draw bacteriostatic water slowly
  3. 3 Inject water along vial side
  4. 4 Gently roll to mix—avoid vigorous shaking
  5. 5 Verify solution clarity; cloudiness indicates degradation
  6. 6 Label with date and concentration
  7. 7 Refrigerate immediately, use within 30 days

Interactions

++
Ipamorelin
Complementary GH release via different receptor pathways. Popular combination.
synergistic
++
GHRP-6
Amplifies GH pulse when combined.
synergistic
++
GHRP-2
Potent combination maximizing GH through dual pathways.
synergistic
~
Hexarelin
Can combine but watch for excessive GH elevation.
monitor
!
CJC-1295 with DAC
Choose one variant based on desired release kinetics.
avoid
~
Tesamorelin
Both are GHRH analogs; combining offers no additional benefit.
monitor
+
MK-677
Different mechanisms; continuous ghrelin versus pulsatile GHRH.
compatible

What to Expect

Day 1-7
Improved sleep quality; vivid dreams from enhanced REM
Week 2-4
Enhanced workout recovery, reduced muscle soreness, better pumps
Week 4-8
Noticeable skin improvements, minor body composition shifts
Week 8-12
Significant lean gains, fat loss, improved joint comfort
Week 12+
Continued gradual improvements in composition and well-being

Side Effects & Safety

Common Side Effects

  • Generally well-tolerated at recommended doses
  • Temporary facial flushing/warmth (5-10 minutes post-injection)

Stop Signs - Discontinue if:

  • Persistent joint pain or carpal tunnel symptoms
  • Significant water retention or edema
  • Unexplained headaches or vision changes
  • Extreme fatigue or lethargy
  • Allergic reaction signs at injection sites

Contraindications

  • Active cancer (due to growth-promoting effects)
  • Diabetic retinopathy
  • Severe kidney disease
  • Pregnancy or breastfeeding

Quality Checklist

Good Signs

  • Vendor provides certificates of analysis (>98% purity)
  • Proper cold-chain shipping with ice packs/refrigeration
  • Vacuum-sealed vials showing pressure seal integrity
  • White/off-white lyophilized powder

Warning Signs

  • Verify expiration dates; lyophilized peptides stable ~2 years if stored properly

Bad Signs

  • Pre-reconstituted solutions—peptide degrades rapidly
  • Discolored powder (yellow/brown indicates degradation)
  • Cloudy solution after reconstitution

References

  • Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
    Jette, L., et al.
    Endocrinology (2005)

    Identified CJC-1295 as a tetrasubstituted hGRF(1-29) analog that covalently binds albumin. Showed 4-fold increase in GH area under the curve compared to native hGRF(1-29) in rat pituitary cells.

  • Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
    Teichman, S.L., et al.
    Journal of Clinical Endocrinology & Metabolism (2006)

    Single injection of CJC-1295 produced dose-dependent 2- to 10-fold increases in GH for 6+ days and 1.5- to 3-fold increases in IGF-I for 9-11 days in healthy adults. Estimated half-life of 5.8-8.1 days.

  • Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
    Ionescu, M., et al.
    Journal of Clinical Endocrinology & Metabolism (2006)

    GH secretion was increased after CJC-1295 with preserved pulsatility. Basal (trough) GH levels were markedly increased (7.5-fold), demonstrating that CJC-1295 maintains natural GH pulse patterns.

  • Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
    Alba, M., et al.
    American Journal of Physiology - Endocrinology and Metabolism (2006)

    Once-daily CJC-1295 maintained normal body composition and growth in GHRH knockout mice, demonstrating efficacy in restoring GH axis function in GH-deficient animal models.

  • Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
    Ionescu, M., et al.
    Growth Hormone & IGF Research (2009)

    CJC-1295 administration in normal adults activated the GH/IGF-1 axis and produced measurable serum protein profile changes, providing biomarker evidence for sustained GHRH analog activity.

Related Peptides

Ipamorelin synergistic

Complementary GH release via different receptor pathways. Popular combination.

GHRP-6 synergistic

Amplifies GH pulse when combined.

GHRP-2 synergistic

Potent combination maximizing GH through dual pathways.

MK-677 compatible

Different mechanisms; continuous ghrelin versus pulsatile GHRH.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.